ARTICLE | Finance

Trubion taken out

Emergent goes business building with Trubion takeout

August 16, 2010 7:00 AM UTC

A lot more money went into autoimmune and cancer company Trubion Pharmaceuticals Inc. (NASDAQ:TRBN) than its current investors are likely to see via Emergent BioSolutions Inc.'s acquisition in a cash and stock deal. But they probably don't care, as they're getting a 52% premium to Trubion's close at $3 last Thursday, before the deal was announced.

The deal values Trubion at $4.55 per share, or $96.8 million. Each share will convert to $1.365 per share in cash, for a total of $38.7 million, and 0.1641 shares of Emergent (NYSE:EBS)...